16772

Distribution of dermatologists in the urban setting: Comparing zip codes with high and low representation of African Americans




Nathan Vengalil, BA, University of Michigan Medical School; Mio Nakamura, MD, MS, University of Michigan; Yolanda R. Helfrich, MD, Department of Dermatology, University of Michigan


To adequately care for the community, one dermatologist is required per 25,000 people. This requirement is not met in the U.S; concomitantly, a non-uniform geographic distribution exists, as dermatologists tend to prefer practicing in the urban setting. No studies to date have characterized dermatologists' locations within cities and its relationship with neighborhood demographics such as ethnicity. African Americans suffer from inferior access to care compared with Whites across health care. By comparing dermatologists' distribution in urban zip codes with high and low representation of African Americans, this study aimed to further define this disparity. We utilized national census data from 2010 to first identify zip codes with populations greater than 25,000 people, as these theoretically should have at least 1 dermatologist. Next, we ordered these zip codes by the percentage of African Americans and identified high (85th percentile) and low (15th percentile) groups. We subsequently utilized the physician database Definitive Healthcare to identify the number of dermatologists in these zip codes. We found that zip codes with high percentage of African Americans have an average of 1.02 dermatologists (1 per 39,367.50 people), which is below the adequate limit. Zip codes with a low percentage of African Americans averaged 2.94 dermatologists (1 per 13,999.88 people), which is above the adequate limit. These findings highlight the barrier that urban African Americans have in accessing dermatologists, specifically due to lack of proximity to a dermatologist. There is a need to expand practice locations to urban areas with high representation of African Americans.

Commercial disclosure: None identified.

16774

Gold photothermal therapy on acne of Asians: Preliminary study





Commercial disclosure: None identified.

16786

Are new molecular tests for melanoma affecting clinical practice among pigmented lesion experts?



Laura J. Gardner, MD, University of Utah School of Medicine; Amir Varedi, MD, MPH, Douglas Grossman, MD, PhD, Huntsman Cancer Institute

Background: Three commercial tests based on gene expression profiling (GEP) are designed to improve diagnostic and/or prognostic accuracy for melanoma and are currently available for use. However, routine GEP testing is not recommended in clinical care guidelines and it is unclear how these tests are being used in clinical practice.


Methods: We investigated the use of these tests by pigmented lesion experts using a survey platform (https://jotform.com) that was disseminated by email to 50 pigmented lesion experts, most of whom are members of the Pigmented Lesion Subcommittee of the ECOG/SWOG Melanoma Prevention Working Group.

Results: Response rate was 84%, most of whom manage pigmented lesions as a majority of their clinical practice (79%). Use of the myPath Melanoma, PLA, and Decision-Dx tests was 21%, 21%, and 29%, respectively, and 63% of the respondents using these tests reported that test results impacted patient management. Users of these tests ordered them on average less than once per month. Years in practice or percent of practice devoted to pigmented lesions did not correlate with test use. Respondents not ordering GEP tests perceived lack of utility, need for further validation studies, and reluctance to practice outside clinical guidelines.

Discussion: Some pigmented lesion experts are using these tests to guide patient management, but most felt further studies are needed for their adoption into clinical practice. Prospective clinical trials are needed to determine whether actions based on these different test results can improve patient outcomes.

Commercial disclosure: None identified.

16818





Simon G. Danby, BSc, PhD, Sheffield Dermatology Research, University of Sheffield; Paul Andrew, University of Sheffield; Linda Kay, BSc, PhD, RSci, Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield; Abigail Pinnock, BSc, PhD, John Chittock, University of Sheffield; Kirsty Brown, BSc, Sheffield Dermatology Research, University of Sheffield; Michael J. Cork, BSc, MB, PhD, FRCPProfessor, University of Sheffield;

Introduction: The skin of atopic dermatitis (AD) patients is characterised by abnormal stratum corneum (SC) lipid levels. Consequently, the lamellar matrices are disrupted and skin barrier function is diminished, increasing skin sensitivity to irritants and allergens.

Objective: To investigate whether a cream containing skin lipids (ceramides, triglycerides and cholesterol) in a multivesicular emulsion can reinforce the skin bearier.

Methods: A double-blind intrasubject-controlled study in 34 people (aged 20-89), prone to AD, with dry skin was conducted. Each participant underwent 4 weeks treatment with the test cream on one forearm and lower leg and a reference emollient cream on the other (randomized). Skin properties were determined before and after treatment. Lipid structure was assessed using FTIR spectroscopy.

Results: Skin barrier integrity was greater at sites treated with the test cream, as indicated by a lower transepidermal water loss after tape-stripping (37.1 \pm 2.2 verses 62.5 \pm 3.0 g/m²/h, P < .0001). Sites treated with the test cream displaced greater SC lipid levels (by 30 \pm 4%) and increased lipid chain ordering (enhanced structure, P < .0001). Lipid changes were significantly associated with skin barrier integrity (r0.608). Compared with the reference, treatment with the test cream increased hydration (P < .0001), decreased dryness (P = .0043) and reduced sodium lauryl sulphate—induced irritation (P < .0001).

Conclusions: The test cream delivers essential skin lipids deep within the SC where they reinforce the skin barrier and protect the skin from dryness and irritation. Compared with the reference emollient cream, commonly prescribed in the UK, the test cream is highly suited to the management of dry, sensitive, skin.

Commercial disclosure: The study was funded by L'Oreal Active Cosmetics Division.

December 2020 JAM Acad Dermatol AB71